Each study seems to show that the next medication is at least as good as or better than the previous ones are
While all three are part of a class of drugs known as GLP-1s (short for glucagon-like peptide 1 receptor agonist), they have different indications and, therefore, different eligibility requirements
Studies and patient reports show that many patients see their weight rebound soon after stopping the injections
First: a once-weekly subcutaneous injection of semaglutide 1.0 mg (Ozempic), a glucagon-like peptide 1 analogue, was approved for the treatment of type 2 diabetes, and has proven to reduce the risk of cardiovascular events in people with type 2 diabetes and cardiovascular disease
When starting on a GLP-1, your appetite is going to decrease because it slows gastric emptying, and also works on the brain to control hunger